Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Ugeskrift for Laeger
|
June 16, 2023
Christian Philip Fischer, Christian Skou Eriksen
Cureus
|
May 10, 2024
Neuroborreliosis Presenting as Encephalitis: A Case Report
Sabina David Ruban, Nanna Skaarup Andersen, Alena Svatkova, et al.
Plos One
|
October 14, 2009
Calprotectin--a novel marker of obesity
Ole Hartvig Mortensen, Anders Rinnov Nielsen, Christian Erikstrup, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 14, 2008
Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass
Anders Rinnov Nielsen, Pernille Hojman, Christian Erikstrup, et al.
BMC Infectious Diseases
|
September 3, 2025
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)
Karen Brorup Heje, Magnus Søltoft Lindhardt, Alessandra Meddis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Ugeskrift for Laeger
|
June 16, 2023
Christian Philip Fischer, Christian Skou Eriksen
Cureus
|
May 10, 2024
Neuroborreliosis Presenting as Encephalitis: A Case Report
Sabina David Ruban, Nanna Skaarup Andersen, Alena Svatkova, et al.
Plos One
|
October 14, 2009
Calprotectin--a novel marker of obesity
Ole Hartvig Mortensen, Anders Rinnov Nielsen, Christian Erikstrup, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 14, 2008
Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass
Anders Rinnov Nielsen, Pernille Hojman, Christian Erikstrup, et al.
BMC Infectious Diseases
|
September 3, 2025
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)
Karen Brorup Heje, Magnus Søltoft Lindhardt, Alessandra Meddis, et al.
Page
of 1